- Home
- IART vs XNCR Comparison
IART vs XNCR Comparison
Compare IART & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IART | XNCR |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | 4427 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 881.9M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IART | XNCR |
|---|---|---|
| Price | $15.09 | $11.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $14.33 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.1M | 712.4K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $8.70 | $6.92 |
| 52 Week High | $16.42 | $18.69 |
Technical Indicators
Market Signals| Indicator | IART | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 42.24 |
| Support Level | $12.64 | $11.02 |
| Resistance Level | $16.35 | $13.28 |
| Average True Range (ATR) | 0.91 | 0.72 |
| MACD | 0.11 | -0.16 |
| Stochastic Oscillator | 90.11 | 24.53 |
Price Performance
Historical ComparisonAbout IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.